SCA
BIO icon

SAC Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

SAC Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,407
Closed -$270K – 1776
2013
Q2 		$270K Buy
+2,407
New +$282K ﹤0.01% 1338

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's BIO Position: Q3 2013 in Review

SAC Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2013, closing a stake of 2,407 shares — an estimated $270K sold.

SAC Capital Advisors first reported a position in BIO in Q2 2013 and held it in 1 quarter. The position peaked at $270K in Q2 2013. 203 funds tracked by Wall St. Rank hold BIO as of Q3 2013.

  • SAC Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 2,407 Bio-Rad Laboratories Class A shares in Q3 2013, an estimated $270K.
  • SAC Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Bio-Rad Laboratories Class A position peaked at $270K in Q2 2013.
  • 203 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2013.

Based on SAC Capital Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.